fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Semaglutide and how it makes you want to eat less

Written by | 16 Jun 2023

Deborah Evans is superintendent pharmacist and clinic director at Remedi Health, an independent pharmacy and healthcare clinic in Winchester. Remedi Health runs a weight management service and has… read more.

Could pharmacist-prescribing reduce chemotherapy errors?

Written by | 24 May 2023

Shannon Nally is a pharmacist with a strong background in aseptic pharmacy work and oncology. Whilst studying for a master’s degree at University College Cork (UCC) she undertook… read more.

How investment could help reduce chemotherapy prescribing errors

Written by | 23 May 2023

Chemotherapy prescribing is an “error-prone process” according to Shannon Nally, the author of a study conducted at University Hospital, Limerick. The findings suggest that prescribing of chemotherapy by… read more.

Investigating chemotherapy prescribing errors

Written by | 22 May 2023

Shannon Nally is a pharmacist with a strong background in aseptic pharmacy work and oncology. Whilst studying for a master’s degree at University College Cork (UCC) she undertook… read more.

Semaglutide for obesity treatment

Written by | 13 May 2023

Alex Miras is Professor of Endocrinology at the University of Ulster, UK and is an expert in obesity management and research. In 2021 a trial of semaglutide for… read more.

Could semaglutide prevent cardiometabolic disease?

Written by | 12 May 2023

Professor Alex Miras, consultant endocrinologist at the University of Ulster, takes the view that obesity is a disease. He explains why this is and how the SELECT trial… read more.

Do I need semaglutide and how can I get it?

Written by | 11 May 2023

Semaglutide works well on its own as obesity treatment but it works even better with the support and guidance of a multi-disciplinary weight-management team, according to Alex Miras,… read more.

NICE recommends semaglutide for obesity

Written by | 10 May 2023

In March 2023 the National Institute for Health and Care Excellence (NICE) published Technology Appraisal Guidance for semaglutide for obesity. Professor Alex Miras explains the guidance and its… read more.

Semaglutide – a game-changer in obesity management

Written by | 9 May 2023

Alex Miras is Professor of Endocrinology at the University of Ulster, UK and is an expert in obesity management and research. In 2021 a trial of semaglutide for… read more.

Deprescribing to optimise drug therapy

Written by | 27 Apr 2023

Debi Bhattacharya is Professor of Behavioural Medicine at the University of Leicester, UK. As a former primary care pharmacist, she has experience of both practice and research into… read more.

CHARMER – a different kind of deprescribing intervention study

Written by | 26 Apr 2023

The CHARMER study of a proactive deprescribing intervention is different from previous studies and addresses five critical factors identified by prescribers and patients as being key to success,… read more.

Barriers and enablers for deprescribing

Written by | 25 Apr 2023

There is no ‘one-size-fits-all’ deprescribing intervention and a good understanding of the barriers and enablers to effective deprescribing is needed, according to Debi Bhattacharya, Professor of Behavioural Medicine… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.